Investigation of the Impact of <i>CYP3A5</i> Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling

• Main Authors: Qingfeng He (Author), Fengjiao Bu (Author), Hongyan Zhang (Author), Qizhen Wang (Author), Zhijia Tang (Author), Jing Yuan (Author), Hai-Shu Lin (Author), Xiaoqiang Xiang (Author)
• Format: Book
• Published: MDPI AG, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Wuzhi capsule (WZC) is commonly prescribed with tacrolimus in China to ease drug-induced hepatotoxicity. Two abundant active ingredients, schisantherin A (STA) and schisandrin A (SIA) are known to inhibit CYP3A enzymes and increase tacrolimus's exposure. Our previous study has quantitatively de...